🇺🇸 FDA
Patent

US 8043623

Immunogenic peptides for the treatment of prostate and breast cancer

granted A61KA61K2039/53A61K2039/57

Quick answer

US patent 8043623 (Immunogenic peptides for the treatment of prostate and breast cancer) held by The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services expires Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services
Grant date
Tue Oct 25 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/53, A61K2039/57, A61K2239/49, A61K2239/58